- The disease
- Focal segmental glomerulosclerosis (FSGS) is a rare disease in which scar tissue forms on parts of the kidney's glomeruli — the tiny structures that filter waste from the blood. This scarring reduces the kidney's ability to filter properly, allowing protein to leak into the urine (a condition called proteinuria). FSGS is one of the leading causes of nephrotic syndrome and can progress to kidney failure. There is currently no therapy specifically approved by the US Food and Drug Administration (FDA) for FSGS, and patients are typically managed with supportive treatments such as angiotensin receptor blockers (ARBs), which reduce protein leakage but do not halt disease progression.
- What the asset is trying to do
- DMX-200 is a G protein-coupled receptor (GPCR) modulator being developed by Dimerix. The precise molecular target of DMX-200 is not disclosed in the available data. DMX-200 is administered on top of background ARB therapy, meaning the trial is evaluating whether adding DMX-200 to standard supportive care provides benefit over ARB alone (per ClinicalTrials.gov NCT05183646).
- What the trial is measuring, and why it matters
- The Phase 3 trial, named ACTION3, is measuring the efficacy and safety of DMX-200 against placebo in FSGS patients already receiving an ARB (per ClinicalTrials.gov NCT05183646). The primary endpoint has not been explicitly stated in the available input data, but proteinuria reduction (commonly measured as urine protein-to-creatinine ratio, or UPCR) is the standard regulatory endpoint in FSGS trials. Secondary endpoints are also not disclosed in the available data. In March 2026, Dimerix announced that the last patient received their first dose, and separately completed a statistical review of the trial's assumptions (per ASX announcements, 9 March 2026 and 27 April 2026).
- Efficacy benchmarks in this setting
- In FSGS, approved benchmarks are limited because no therapy has received standard FDA approval specifically for this disease. Sparsentan, a dual endothelin and angiotensin receptor antagonist, received accelerated approval from the FDA in February 2023 for reducing proteinuria in adults with primary FSGS based on a 36-week reduction in UPCR of approximately 41% versus irbesartan (an ARB) in the DUPLEX trial (per Travere Therapeutics prescribing information and FDA approval documentation). In an earlier Phase 2 study, Dimerix reported proteinuria-reduction data for DMX-200, but those figures are from a smaller, earlier-stage study and are not statistically comparable to the Phase 3 ACTION3 trial results, which are not yet available (per ClinicalTrials.gov NCT05183646).
- Commercial context
- As of the available data, there is no therapy with standard (non-accelerated) FDA approval specifically indicated for FSGS, making the regulatory landscape active for new entrants. In June 2026, Dimerix announced a licence agreement granting Everest Medicines rights to DMX-200 for China and the Asia region (per ASX announcement, 16 June 2026); financial terms of that agreement are not disclosed in the available input data and should be sourced directly from the announcement. DMX-200 appears to be Dimerix's lead clinical asset based on the information provided.